Skip to content
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY
Board of Directors
IR & Media
Presentations & articles
Subscribe to press releases
Articles of Association
Board of Directors
Presentations & Articles
ABGSC Investor Day
CEO Magnus Corfitzen presents at ABG Investor Day
HC Andersen – Oncology Seminar
Chief Executive Officer presents at HC Andersen Oncology Seminar
Erik Penser Bank – Company Day
Chief Executive Officer presents at Erik Pensers Company Day
Redeye Orphan Drug Day
Chief Medical Officer, Carl Bjartmar presents at Redeye Orphan Drug Day
Erik Penser Bank – Life Science day
Chief Commercial Officer Julie Waras Brogren presents at Erik Pensers Life Science day
Ascelia Pharma – Aktiedagen in Lund 2022
Chief Commercial Officer presents at Aktiedagen in Lund
Redeye Fight Cancer Seminar 2022
VP of R&D Andreas Norlin presents at Redeye Fight Cancer Seminar
HC Andersen Capital seminar – Re-read Study Orviglance vs. Gadolinium
CEO Magnus Corfitzen presents results from the re-read study vs. a gadolinium contrast agent (presentation in Danish)
Erik Penser Bank – Company day
CEO Magnus Corfitzen presents at Erik Penser company day.
Redeye Life Science Day 2021
Ascelia Pharma CEO Magnus Corfitzen presents at Redeye Life Science Day.
Q3 2021 Financial Presentation
The Executive Managment in Ascelia Pharma presents a business update and the quarterly results
HC Andersen/Nordea Small & Mid Cap Seminar
CEO Magnus Corfitzen presents at the Danish HC Andersen/Nordea Small & Mid cap seminar (presentation in Danish)
Erik Penser Bank – Orphan Drugs Day
CEO Magnus Corfitzen presents how Ascelia Pharma advances orphan drugs
Swedish Shareholders’ Association
CMO Carl Bjartmar presents Ascelia Pharma at the Swedish Shareholders' Association's share day
Clinical collaboration with Taiho Oncology
CEO Magnus Corfitzen presents the clinical collaboration with Taiho Oncology (in Danish)
HC Andersen Life Science Seminar
CEO Magnus Corfitzen presents at HC Andersen Life Science Seminar (in Danish)
Redeye Growth Day
CEO Magnus Corfitzen presents at Redeye Growth Day 2021
Redeye Orphan Drugs seminar
CEO Magnus Corfitzen presents at Redeye Orphan Drugs seminar
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headqu ...
Ascelia’s employees are passionate and driven to develop products that will help people with rare cancer conditions live longer and healthier lives.
Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical standards of our industry COURAGE We work tirelessly and follow our convictions even when it means changing status quo FOCUS We are devoted to i ...
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Choose what kind of cookies to accept. Your choice will be saved for one year.
These cookies are not optional. They are needed for the website to function.
In order for us to improve the website's functionality and structure, based on how the website is used.
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.